35613-84-4

Basic information

• Product Name: N'-Hydroxy-2-methylpropanimidamide
• Synonyms: N-HYDROXY-2-METHYLPROPANIMIDAMIDE;N-HYDROXYISOBUTYRAMIDINE;N'-Hydroxy-2-methylpropaneimideamide;Isobutyramidoxime;N-Hydroxyisobutanamidine;Isobutanamidoxime;Isobutyramide oxime;Isopropylcarboxamide oxime
• CAS NO: 35613-84-4
• Molecular Formula: C₄H₁₀N₂O
• Molecular Weight: 102.14
• Product Categories: pharmacetical
• Mol File: 35613-84-4.mol

Chemical Properties

• Melting Point: 60 °C
• Boiling Point: 146℃
• Flash Point: 42℃
• Appearance: /
• Density: 1.09
• Vapor Pressure: 0.0533mmHg at 25°C
• Refractive Index: 1.477
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform, Methanol
• PKA: 15.04±0.50(Predicted)
• CAS DataBase Reference: N'-Hydroxy-2-methylpropanimidamide(CAS DataBase Reference)
• NIST Chemistry Reference: N'-Hydroxy-2-methylpropanimidamide(35613-84-4)
• EPA Substance Registry System: N'-Hydroxy-2-methylpropanimidamide(35613-84-4)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25
• Safety Statements: 45
• HazardClass: IRRITANT
• Hazardous Substances Data: 35613-84-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N'-Hydroxy-2-methylpropanimidamide is used as an active pharmaceutical ingredient for its antitumor activities. It has been shown to be effective against P388 leukemia, demonstrating its potential in the development of new cancer treatments.
Used in Drug Delivery Systems:
In the field of drug delivery, N'-Hydroxy-2-methylpropanimidamide can be utilized as a component in the development of novel drug delivery systems. Its properties may contribute to enhancing the delivery, bioavailability, and therapeutic outcomes of various pharmaceuticals, particularly in cancer treatment.

InChI:InChI=1/C4H10N2O/c1-3(2)4(5)6-7/h3,7H,1-2H3,(H2,5,6)

Upstream product

• 78-82-0 Isobutyronitrile 
• 625-28-5 Isovaleronitrile 
• 849833-56-3 N-hydroxyisobutyramidine 

Downstream Products

• 1254169-59-9 2-(2-chloro-6-fluorophenyl)-5-(6-(3-isopropyl-1,2,4-oxadiazol-5-yl)pyridin-3-yl)-1H-imidazole-4-carbonitrile 
• 1254168-86-9 5-(2-(2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl)benzofuran-5-yl)-3-isopropyl-1,2,4-oxadiazole 
• 1217336-69-0 2-(4-fluorophenyl)-5-(3-(3-isopropyl-1,2,4-oxadiazol-5-yl)phenyl)-N-methylbenzofuran-3-carboxamide 
• 1040337-24-3 2-(3-isopropyl-1,2,4-oxadiazol-5-yl)aniline 
• 1393843-03-2 2-(2-chloro-6-fluorophenyl)-4,4-dimethyl-7-[3-(propan-2-yl)-1,2,4-oxadiazol-5-yl]-1,4-dihydro chromeno[3,4-d]imidazole 
• 1430745-98-4 3-isopropyl-5-((1R,3s,5S)-3-((1r,4R)-4-(5-(methylsulfonyl)pyrazin-2-yloxy)cyclohexyloxy)-8-azabicyclo[3.2.1]octan-8-yl)-1,2,4-oxadiazole 
• 1430746-04-5 3-isopropyl-5-((1R,3s,5S)-3-((1r,4R)-4-(2-methyl-6-(methylsulfonyl)pyridin-3-yloxy)cyclohexyloxy)-8-azabicyclo[3.2.1]octan-8-yl)-1,2,4-oxadiazole 
• 1430746-00-1 3-isopropyl-5-((1R,3s,5S)-3-((1r,4R)-4-(4-(methylsulfonyl)phenoxy)cyclohexyloxy)-8-azabicyclo[3.2.1]octan-8-yl)-1,2,4-oxadiazole 
• 1596358-17-6 3-isopropyl-5-(4'-nitrophenyl)-1,2,4-oxadiazole 
• 906540-95-2 N'-[[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]carbonyl]oxy]-2-methylpropanimidamide 
• 1071520-63-2 4-(3-fluorobenzoyl)piperazine-1-carboxylic acid [4-(3-isopropyl[1,2,4]oxadiazol-5-yl)phenyl]amid 
• 1071521-24-8 4-(3-fluorobenzoyl)piperazine-1-carboxylic acid [3-(3-isopropyl[1,2,4]oxadiazol-5-yl)phenyl]amide 
• 1132841-11-2 C₇H₁₀N₂O₃ 

Relevant articles and documents

Novel O-acylated amidoximes and substituted 1,2,4-oxadiazoles synthesised from (+)-ketopinic acid possessing potent virus-inhibiting activity against phylogenetically distinct influenza A viruses

This article describes the synthesis and antiviral activity evaluation of new substituted 1,2,4-oxadiazoles containing a bicyclic substituent at position 5 of the heterocycle and O-acylated amidoximes as precursors for their synthesis. New compounds were

Development of a Raltegravir-based Photoaffinity-Labeled Probe for Human Immunodeficiency Virus-1 Integrase Capture

Photoaffinity labeling (PAL) is one of the upcoming and powerful tools in the field of molecular recognition. It includes the determination of dynamic parameters, such as the identification and localization of the target protein and the site of drug binding. In this study, a photoaffinity-labeled probe for full-length human immunodeficiency virus-1 integrase (HIV-1 IN) capture was designed and synthesized, following the structure of the FDA-approved drug Raltegravir. This photoprobe was found to retain the HIV IN inhibitory potential in comparison with its parent molecule and demonstrates the ability to label the HIV-1 IN protein. Putative photoprobe/inhibitor binding sites near the catalytic site were then identified after protein digestion coupled to mass and molecular modeling analyses.

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with CNS disorders. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating cognitive impairment associated with CNS disorders in a subject in need or at risk thereof, including age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI, Age-Associated Memory Impairment, Age Related Cognitive Decline, dementia, Alzheimer's Disease(AD), prodromal AD, PTSD, schizophrenia, bipolar disorder, ALS, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes

As a potential treatment of type 2 diabetes, a novel PPARγ non-TZD full agonist, compound 18 (BR102375) was identified from the original lead BR101549 by the SAR efforts of the labile metabolite control through bioisosteres approach. In vitro assessments

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

Substituted aminopyrimidine compounds and their method and use thereof

The invention relates to a new aminopyrimidine compound and an application thereof as a drug for treating disorder or diseases related to PI3-kinase abnormity in a free form or a pharmaceutically acceptable salt and preparation form. The invention also relates to a pharmaceutical composition which contains the new aminopyrimidine compound and an application of the pharmaceutical composition in treating mammal disorder or diseases and especially treating human disorder or diseases related to the PI3-kinase abnormity, such as treatment of immunity and inflammatory diseases of PI3-kinase regulation which plays a leading role in a leucocyte function and treatment of proliferative diseases which are related to PI3-kinase activity and include but not limited to leukaemia and solid tumor.

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5- containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age- Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer' s Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson' s disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.

COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT

The present invention relates to a novel compound having a GPR1 19 agonistic activity, a method for preparing the same, and a pharmaceutical composition including the same as an effective component. The present invention has an effective hypoglycemic acti

COMPOUNDS AS HEPATITIS C INHIBITORS AND USES THEREOF IN MEDICINE

Provided herein are compounds as hepatitis C inhibitors and uses thereof in medicine. Specifically, provided herein is a compound of Formula (I) or a stereoisomer, a tautomer, an enantiomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or hepatitis C diseases. Also provided herein are a pharmaceutically acceptable composition containing such compound and a method of treating HCV infection or hepatitis C diseases comprising administering the compound or pharmaceutical composition thereof disclosed herein.

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a a5- containing GABAA receptor agonist (e.g., a α5 -containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.